1. Home
  2. RS vs IKT Comparison

RS vs IKT Comparison

Compare RS & IKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

RS

Reliance Steel & Aluminum Co. (DE)

HOLD

Current Price

$393.04

Market Cap

20.0B

Sector

Industrials

ML Signal

HOLD

Logo Inhibikase Therapeutics Inc.

IKT

Inhibikase Therapeutics Inc.

HOLD

Current Price

$1.91

Market Cap

220.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RS
IKT
Founded
1939
2008
Country
United States
United States
Employees
N/A
N/A
Industry
Metal Fabrications
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
20.0B
220.5M
IPO Year
1996
2020

Fundamental Metrics

Financial Performance
Metric
RS
IKT
Price
$393.04
$1.91
Analyst Decision
Buy
Strong Buy
Analyst Count
6
5
Target Price
$358.00
$5.00
AVG Volume (30 Days)
328.5K
596.7K
Earning Date
04-22-2026
03-26-2026
Dividend Yield
1.39%
N/A
EPS Growth
N/A
57.76
EPS
5.10
N/A
Revenue
$14,805,900,000.00
N/A
Revenue This Year
$10.16
N/A
Revenue Next Year
$0.82
N/A
P/E Ratio
$79.29
N/A
Revenue Growth
N/A
N/A
52 Week Low
$260.31
$1.33
52 Week High
$419.83
$2.26

Technical Indicators

Market Signals
Indicator
RS
IKT
Relative Strength Index (RSI) 51.79 67.45
Support Level $284.20 $1.63
Resistance Level $419.83 $1.91
Average True Range (ATR) 12.07 0.08
MACD -2.38 0.03
Stochastic Oscillator 14.90 92.31

Price Performance

Historical Comparison
RS
IKT

About RS Reliance Steel & Aluminum Co. (DE)

Reliance Inc operates a network of companies providing diversified metal solutions and is the metals service center company. It distributes a full line of over 100,000 metal products, including alloy, aluminum, brass, copper, carbon steel, stainless steel, titanium and other specialty steel products. The company services more than 125,000 customers in a variety of industries, including consumer products, general manufacturing, non-residential construction, transportation, aerospace, energy, electronics and semiconductor fabrication, industrial machinery and heavy industry. It also services the auto industry, through its toll processing operations where it processes customer-owned metal for a fee.

About IKT Inhibikase Therapeutics Inc.

Inhibikase Therapeutics Inc a clinical-stage pharmaceutical company developing therapeutics to modify the course of cardiopulmonary diseases, namely, Pulmonary Arterial Hypertension (PAH), in which aberrant signaling through type III receptor tyrosine kinases, including platelet derived growth factor receptors and a stem cell factor receptor, known as c-Kit, has been implicated. Its product candidate is IKT-001, a prodrug of imatinib mesylate (imatinib), for PAH which is an orphan indication. The company has developed its own portfolio of protein kinase inhibitors to treat bacterial and viral infections, including viral infections in the brain. It has one reporting segment, which is the business of developing protein kinase inhibitor therapeutics.

Share on Social Networks: